

## Investigational Trials of Idecabtagene Vicleucel (ide-cel; bb2121) in Patients With Multiple Myeloma



A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)<sup>1-3</sup>


## CURRENTLY ENROLLING GLOBALLY NCT03651128 Phase 3 PRIMARY ENDPOINT SELECT SECONDARY ENDPOINTS PFS OS, EFS, ORR, MRD, CR rate, DOR, TTR, AEs, and pharmacokinetics KEY ELIGIBILITY CRITERIA **TREATMENT FOLLOW-UP** Arm A: bb2121 (n=~254) 150-450 x 10<sup>6</sup> CAR+ T cells. • R/R multiple myeloma with 2-4 prior ollowing leukapheresis, bridging therapy PFS lines of treatment (optional), and lymphodepletion follow-up period Refractory to the last anti-myeloma until PD Follow up for safety and survival treatment regimen prior to study entry (documented PD during treatment or Arm B: standard regimens. within 60 days of completion) investigator's choice (n=~127) Long-term Previous treatment with daratumumab. DPd. or follow-up protocol a proteasome inhibitor, and an (up to 15 years after last Option for those who immunomodulatory compound-containing DVd, or discontinue due to PD: bb2121 infusion) regimen for ≥2 consecutive cycles • IRd, or Previously achieved a response to at least 150-450 x 106 CAR+ T cells. 1 prior treatment EPd, or following leukapheresis, • **ECOG PS** ≤1 bridging therapy (optional), Kd and lymphodepletion

CONTACT: ClinicalTrialDisclosure@bms.com





A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High-Risk, Newly Diagnosed Multiple Myeloma<sup>3-5</sup>



CONTACT: ClinicalTrialDisclosure@bms.com

ALSO ENROLLING NCT03601078 Phase 2

A Phase 2, Multicohort, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma<sup>6</sup>

CONTACT: ClinicalTrialDisclosure@bms.com

Idecabtagene vicleucel (ide-cel; bb2121) in collaboration with bluebird bio™.

The safety and efficacy of idecabtagene vicleucel (ide-cel; bb2121) and/or its uses are under investigation and have not been established.

There is no guarantee that idecabtagene vicleucel (ide-cel; bb2121) will receive health authority approval or become commercially available in any country for the uses being investigated.